GlycoMimetics Inc. (NASDAQ:GLYC) VP Helen M. Thackray sold 4,000 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $7.00, for a total value of $28,000.00. Following the transaction, the vice president now directly owns 156,715 shares in the company, valued at $1,097,005. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

GlycoMimetics Inc. (NASDAQ:GLYC) opened at 6.63 on Wednesday. GlycoMimetics Inc. has a 12-month low of $3.70 and a 12-month high of $9.25. The company’s market cap is $152.86 million. The firm has a 50-day moving average price of $7.37 and a 200-day moving average price of $7.19.

A number of research analysts have recently issued reports on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $12.00 price target on shares of GlycoMimetics in a report on Sunday, August 7th. Stifel Nicolaus upped their price target on GlycoMimetics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Friday, August 5th. Zacks Investment Research downgraded GlycoMimetics from a “buy” rating to a “hold” rating in a report on Tuesday, August 9th. SunTrust Banks Inc. assumed coverage on GlycoMimetics in a report on Tuesday, July 26th. They set a “buy” rating and a $16.00 price target on the stock. Finally, Jefferies Group reaffirmed a “buy” rating on shares of GlycoMimetics in a report on Friday, August 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $12.35.

A number of hedge funds and other institutional investors have recently made changes to their positions in GLYC. Strs Ohio acquired a new position in shares of GlycoMimetics during the second quarter valued at $115,000. Barclays PLC increased its stake in GlycoMimetics by 77.1% in the second quarter. Barclays PLC now owns 15,816 shares of the company’s stock valued at $115,000 after buying an additional 6,885 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new stake in GlycoMimetics during the second quarter valued at $143,000. TFS Capital LLC purchased a new stake in GlycoMimetics during the second quarter valued at $149,000. Finally, California State Teachers Retirement System purchased a new stake in GlycoMimetics during the second quarter valued at $156,000. Hedge funds and other institutional investors own 80.28% of the company’s stock.

About GlycoMimetics

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

5 Day Chart for NASDAQ:GLYC

Receive News & Stock Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related stocks with our FREE daily email newsletter.